The immune system plays a crucial role in certain aspects of ALS disease progression. This compound tamps down the immune system by blocking CD40 positive antigen presenting cells from becoming activated macrophage.
Thanks to Ice Bucket Challenge donations, we were able to invest $1.5 million into this program to pay for the manufacturing of 10,000 units of this compound necessary for IND enabling studies and trials through Phase 2B.
A phase IIA trial asks whether Gilenya might have the potential to slow ALS by reducing T cell-mediated inflammation.
Anti-CD40L delays the onset of paralysis and extends the survival of a mouse model of ALS.
Topics in the Pipeline
Register now for our upcoming webinar on May 10th at 6pm: FDA approves Radicava - What do we need to know?
#WHATWOULDYOUGIVE to #ENDALS?
For ALS Awareness Month, join our #InThreeWords campaign on social media.
You can be a hero and give to ALS TDI to help us get more promising treatments out of our lab and into people living with ALS.
November 27 is
You've taken the challenge, now help
move promising treatments out of our
lab and into people living with ALS.
The 2018 Combined Federal Campaign has officially launched!
Help us continue to move more potential treatments into the clinic!
Stay up to date with ALS TDI by subscribing to our newsletter today!
Join the Ride to #EndALS